Viking Therapeutics (VKTX) Equity Average (2016 - 2025)
Historic Equity Average for Viking Therapeutics (VKTX) over the last 11 years, with Q3 2025 value amounting to $754.2 million.
- Viking Therapeutics' Equity Average fell 1767.8% to $754.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.2 million, marking a year-over-year decrease of 1767.8%. This contributed to the annual value of $614.3 million for FY2024, which is 14885.46% up from last year.
- According to the latest figures from Q3 2025, Viking Therapeutics' Equity Average is $754.2 million, which was down 1767.8% from $821.2 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Equity Average registered a high of $927.4 million during Q2 2024, and its lowest value of $139.7 million during Q1 2023.
- Its 5-year average for Equity Average is $448.7 million, with a median of $260.1 million in 2023.
- As far as peak fluctuations go, Viking Therapeutics' Equity Average tumbled by 2852.93% in 2022, and later soared by 35897.3% in 2024.
- Over the past 5 years, Viking Therapeutics' Equity Average (Quarter) stood at $207.5 million in 2021, then decreased by 28.53% to $148.3 million in 2022, then skyrocketed by 141.62% to $358.3 million in 2023, then skyrocketed by 150.01% to $895.9 million in 2024, then decreased by 15.81% to $754.2 million in 2025.
- Its Equity Average stands at $754.2 million for Q3 2025, versus $821.2 million for Q2 2025 and $863.6 million for Q1 2025.